P. Vlummens MD

Targeted therapies in multiple myeloma: new antibodies and CAR-T cells

SUMMARY

New therapeutic antibodies and T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in haematologic malignancies and multiple myeloma (MM). Various designs, manufacturing processes, and study populations, among other variables, have been tested and reported in clinical trials in MM. Here, we review and compare ongoing trials and the results of the reported clinical trials. We also discuss the outlook for CAR-T cell therapies, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all haematologic malignancies.

Is it possible to predict who may never need treatment for B-CLL?

SUMMARY

Chronic lymphocytic leukaemia has a very heterogeneous disease evolution. Prognostic factors of B-CLL overall survival have been extensively studied. However, much less is known about prognostic factors that can identify patients who will never develop an indication for treatment, at the time of their initial diagnosis. In this study we give an overview of variables that have a predictive value for treatment free survival. Subsequently, we try to develop a novel prognostic index, to address the question ‘who will never need treatment for B-CLL?’.

(BELG J HEMATOL 2018;9(3):124–9)

P36 Can CLL-IPI at time of diagnosis predict who may never need treatment for B-CLL?

P30 Severe pancytopenia as presenting feature in newly diagnosed multiple myeloma (NDMM): a rare presentation

P15 Chronic myeloid leukemia initially presenting with acute haemopericardium and cardiac tamponade: case presentation and identification of a possible pitfall

P11 Blastic plasmacytoid dendritic cell neoplasm with skin, bone marrow and CNS involvement: a case report

PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?